Recurrent spontaneous pneumothorax under nintedanib treatment in ınterstitial lung disease associated with systemic sclerosis

Main Article Content

Soner Şenel https://orcid.org/0000-0001-9311-8179
Tuğba kahraman Denizhan https://orcid.org/0000-0001-7007-1160
Melih Kızıltepe https://orcid.org/0000-0001-6100-2024
Emel Oğuz Kökoğlu https://orcid.org/0000-0002-5475-2182
Nuri Tutar https://orcid.org/0000-0003-3097-4896

Keywords

Systemic Sclerosis, Spontaneus pnomotorax, Nintedanib

Abstract

Interstitial lung disease (ILD) is a common complication that can develop during the course of systemic sclerosis (SSc). Nindetanib is an antifibrotic drug approved for the treatment of systemic sclerosis-associated interstitial lung disease. Although there is an insufficient data on the development of pneumothorax, the safety of Nintedanib treatment is also uncertain. We observed recurrent resistant pneumothorax under nintedanib treatment in a patient with systemic sclerosis-associated interstitial lung disease. Nintedanib use may increase the risk of developing refractory pneumothorax. Ssc patients who are started on nintedanib should be followed carefully for pneumothorax.

Downloads

Download data is not yet available.
Abstract 363 | PDF Downloads 279

References

1. Kondoh Y, Makino S, Ogura T, et al. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respir Investig. 2021 Nov;59(6):709-740. doi: 10.1016/j.resinv.2021.04.011.
2. Goh NSL, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1248-54. doi: 10.1164/rccm.200706-877OC.
3. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076.
4. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584.
5. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009 Aug;6(8):465-77. doi: 10.1038/nrclinonc.2009.94.
6. Hideaki Y , Yuta T, Shintaro S et al. Impact of progressive fibrosing interstitial lung disease (ILD) in ILD patients complicated with secondary spontaneous pneumothorax. Sarcoidosis Vasc Diffuse Lung Dis. 2022;38(4):e2021042. doi: 10.36141/svdld.v38i4.11465.

Most read articles by the same author(s)

  • Olcay Aycicek, Erdogan Cetinkaya, Fatma Demirci Ucsular, Nazan Bayram, Abdurrahman Senyigit, Nimet Aksel, Nurhan Atilla, Nurhan Sarioglu, Elif Yelda Niksarlioglu, Ahmet Ilgazli, Talat Kilic, Hulya Gunbatar, Sule Cilekar, Aydanur Ekici, Sibel Arinc, Haci Ahmet Bircan, Dildar Duman, Ozlem Sengoren Dikis, Onur Yazıcı, Abdullah Kansu, Nuri Tutar, Emine Ozsari, Serdar Berk, Yelda Varol, Ahmet Emin Erbaycu, Bunyamin Sertogullarindan, Ali Kadri Cirak, Mustafa Cortuk, Gulistan Karadeniz, Alper Simsek, Cengizhan Sezgi, Fuat Erel, Tuba Ciftci, Aysel Sunnetcioglu, Mehmet Savas Ekici, Ersin Gunay, Meltem Agca, Onder Ozturk, Hamza Ogun, Elif Acar, Omer Tamer Dogan, Dursun Alizoroglu, Esma Gezer, Tevfik Ozlu, Research Burden of Interstitial Lung Diseases in Turkey – RBILD , Sarcoidosis, Vasculitis and Diffuse Lung Diseases: Vol. 39 No. 1 (2022)